Lucid Diagnostics reports Medicare coverage for EsoGuard test
Lucid Diagnostics announced full Medicare reimbursement for the EsoGuard esophageal DNA test, a major milestone for the company. The announcement marks the beginning of a new commercialization phase and includes record test volumes.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed